Navigation Links
Quest Diagnostics Initiates CEO Succession Process
Date:10/25/2011

MADISON, N.J., Oct. 25, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that its Board of Directors has begun the process of identifying a successor to Surya N. Mohapatra, Ph.D., President, Chairman and Chief Executive Officer.  The Board of Directors has formed a search committee, engaged a leading executive recruitment firm and will consider both external and internal candidates.

Dr. Mohapatra has agreed to continue to serve as Chairman and CEO for up to six months to ensure a smooth transition.

Daniel C. Stanzione, Ph.D., Lead Independent Director, said: "Under Surya's leadership Quest Diagnostics has established itself as a patient-focused healthcare company. It has built an engine for growth in esoteric and gene-based testing, focused on the critically important areas of cancer, cardiovascular disease, infectious disease and neurological disorders. The company has a solid foundation for the future, and will continue to focus on delivering strong operating performance and increased shareholder value while we progress through this transition. The company and the healthcare industry have benefited greatly from Surya's leadership and vision."

"I am proud of the Quest Diagnostics team of 42,000 colleagues and what they have accomplished," said Dr. Mohapatra. "In the 12 years I've been with the company, it has been gratifying to see revenues grow five-fold to $7.5 billion and earnings grow at a compound annual rate of 21%. Today, we perform testing for 150 million patients each year, serve over half of America's physicians and hospitals, and have been recognized on Fortune Magazine's list of the World's Most Admired Companies.

"Our passion for patients, drive for growth and commitment to people have made us the world leader in diagnostic testing, information and services. With unmatched assets in science and innovation, information technology and access and distribution now in place, the Board and I agreed that this is the right time to transition to new leadership. It has been truly an honor and privilege to serve as Chairman of the Board and CEO of this great company. "

Dr. Mohapatra joined the company as Chief Operating Officer in February, 1999 and became President later that year.  He was appointed CEO in May, 2004 and was named Chairman of the Board in December, 2004.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: http://www.questdiagnostics.com/.

CONTACT: For Quest Diagnostics: Kathleen Valentine (Investors), +1-973-520-2900, or Gary Samuels (Media), +1-973-520-2800


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Diamonds, silver and the quest for single photons
2. Maryland Stem Cell Research Commission Issues 2012 Requests for Applications (RFAs)
3. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
4. HDS International Comments on Front-end Carbon Sequestration Technologies
5. Quest Diagnostics and Genomic Vision Form Strategic Collaboration to Develop Genome-based Laboratory Tests
6. Clinical Genomics Extends Strategic Alliance for Colorectal Cancer Testing Development with Quest Diagnostics
7. GEN point of view article questions reported costs of drug R&D
8. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
9. FDA Requests Input on Development of User Fee Program for Biosimilar and Interchangeable Biological Products
10. GenomeQuest to Lead Biomarker World Congress Panel on Applying Whole Genome Sequencing to Developing Companion Diagnostics
11. New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... ... of Strategic Planning. His extensive background in consulting, development and marketing make ... marketing and differentiation consulting, business strategy development, new product marketing and global ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... announced that the stock market news outlet had initiated coverage on Interpace ... that screens and identifies exposure, progression and risk analysis from specific cancers ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ (VIC™), ... of directors. This addition continues to strengthen and diversify VIC’s board. , "We ... Chairman. “He is a highly accomplished business executive with a broad range of experience ...
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical Diagnostics, a ... announces the launch of a new NTA biosensor chip for use with its ... the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , “Recombinant proteins ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):